Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults 18 Years of Age or Older With Renal Transplant
Phase of Trial: Phase III
Latest Information Update: 19 Jun 2017
At a glance
- Drugs GSK 1437173A (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms ZOSTER041
- Sponsors GlaxoSmithKline
- 15 Jun 2017 Status changed from active, no longer recruiting to completed.
- 22 Apr 2017 This trial has been completed in Finalnd.
- 21 Apr 2017 This trial has been completed in Belgium.